CClinicalTrials.gg
CompletedNCT02327364Updated Nov 3, 2025

Natural History of Pearson Syndrome

An observational study in Pearson Syndrome, sponsored by Sumit Parikh. Completed. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Sumit Parikh · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
11
Sex
All
01

Study summary

The purpose of this 3-year, multi-site, non-randomized, prospective, observational study is to characterize the natural history of Pearson Syndrome. The Syndrome is a rare mitochondrial disorder due to a large-scale mtDNA deletion. Children typically present in their 1st two years of life (most in infancy) with anemia and/or pancreatitis. Most individuals with Pearson Syndrome die in childhood. Those who survive evolve to Kearns-Sayre Syndrome/Chronic Progressive External Ophthalmoplegia (KSS/CPEO) although accurate survival estimates are not yet known.

Read the detailed description

All patients with confirmed Pearson Syndrome who satisfy the inclusion/exclusion criteria will be offered enrollment into this study. Patients followed at participating NAMDC clinical sites will be enrolled at those sites. Patients who are not followed at participating NAMDC clinical sites and wish to participate may contact one of the member sites directly or their local doctor may direct them to one of the member sites. Both male and female patients from all racial and ethnic backgrounds who satisfy the inclusion and exclusion criteria will be encouraged to participate. Children and adults will be eligible to be enrolled, but we expect the patient population to be mostly children.

Each patient with Pearson Syndrome who enrolls in the NAMDC Clinical Registry will be encouraged to participate in this study. Each patient enrolling in this study will be required to enroll in the NAMDC Clinical Registry either prior to or upon enrolling in this study. Demographic, medical history, biochemical, histological, genetic, and other clinical data from the registry will be incorporated into this study.

Every effort will be made to minimize the inconvenience to patients of participating in this study. The study-related activities at each patient visit will be kept to a maximum of one hour, and will, whenever possible, be scheduled to coincide with the patient's regular follow-up with his or her treating physician. This study is observational and has no associated medical procedures.

02

Conditions studied

  • Pearson Syndrome
03

In context

Lead sponsor

This is the only study on the registry with Sumit Parikh as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with confirmed Pearson Syndrome

Inclusion criteria

  1. All individuals of any age with confirmed Pearson Syndrome are eligible to participate. Pearson Syndrome requires the presence of a large-scale mtDNA deletion along with sideroblastic anemia with or without pancreatic insufficiency.
  2. All patients must agree to participate in the NAMDC Clinical Registry

Exclusion criteria

Exclusion Criteria:

  1. Patient does not fulfill criteria for Pearson Syndrome
  2. Not willing to participate in the NAMDC clinical Registry
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
11 participants (actual)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Track patients with Pearson Syndrome longitudinally

    Time frame: 3 years

Secondary outcomes

  1. Determine genetic and clinical predictors of Pearson Syndrome course

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02327364
Lead sponsor
Sumit Parikh
Collaborators
National Institutes of Health (NIH)
Responsible party
Sumit Parikh (Associate Professor of Neurology, The Cleveland Clinic) — Sponsor-investigator
First posted
Dec 30, 2014
Start date
Mar 2014
Primary completion
Aug 2020
Completion
Aug 2020
Last update
Nov 3, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion